Department of Oncology, Odense University Hospital , Odense , Denmark.
Acta Oncol. 2014 Mar;53(3):385-91. doi: 10.3109/0284186X.2013.820839. Epub 2013 Aug 19.
The purpose was to examine characteristics, treatment and outcome in an unselected, prospectively registered complete population of patients with gastro-oesophageal adenocarcinoma cancer (GEA).
All cases diagnosed with GEA between 2008 and 2009 in the Region of Southern Denmark (pop: 1,200,000) were registered. Patient characteristics, including performance status, stage and therapy, were retrieved from patient charts and used to compare sub-groups of patients.
Three hundred and thirty patients were registered as having GEA. Patients were divided into three clinical subgroups based on initial treatment option: group 1: patients with resectable GEA (n = 113); group 2: patients receiving first-line therapy (n = 107); group 3: patients receiving no tumour-directed therapy (n = 110). Median overall survival (95% CI) in the three groups was 36 months (25-not reached), 7.1 months (7-9) and 2.4 months (2-3), respectively. Seven percent of patients participated in clinical trials.
Among patients not amendable to resection, around 30% are candidates for three-drug combination chemotherapy. Age > 65 years was found not to be a poor prognostic factor for survival, giving the possibility of treating elderly patients in the future. Many patients (approx. 30%), however, never received cancer-directed therapy. In order to improve survival in the entire population, it is important that future trials also focus on this group of patients.
本研究旨在分析未经选择的、前瞻性登记的胃食管腺癌(GEA)患者的特征、治疗方法和预后。
在丹麦南部地区(人口 120 万),2008 年至 2009 年间诊断出的所有 GEA 病例均被登记。从患者病历中提取患者特征,包括一般状况、分期和治疗方法,并用于比较患者亚组。
共登记了 330 例 GEA 患者。根据初始治疗选择将患者分为三个临床亚组:组 1:可切除 GEA 患者(n = 113);组 2:接受一线治疗的患者(n = 107);组 3:未接受肿瘤靶向治疗的患者(n = 110)。三组患者的中位总生存期(95%CI)分别为 36 个月(25-未达到)、7.1 个月(7-9)和 2.4 个月(2-3)。7%的患者参加了临床试验。
在不可切除的患者中,约 30%的患者适合接受三药联合化疗。年龄>65 岁不是生存的不良预后因素,这为未来治疗老年患者提供了可能。然而,许多患者(约 30%)从未接受过癌症靶向治疗。为了提高整个人群的生存率,未来的试验也应关注这组患者。